JPMorgan places Scholar Rock on ‘Positive Catalyst Watch’

JPMorgan placed a “Positive Catalyst Watch” on shares of Scholar Rock (SRRK) with an Overweight rating and $56 price target The firm is “very pleased” the apitegromab applicating for the treatment of children and adults with spinal muscular atrophy was accepted by the FDA with a September 30 action date. The firm believes the data support approval on or before the action date.